Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Response to ASX Cleansing Notice Validity Letter

Friday, January 10, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). The company has also dosed the first patient in its Phase 1/2a clinical study of BetaBart. Additionally, positive updates have been shared across four of its clinical programs.
Price reaction · baseline $4.15 (2025-01-10T16:38:00.000Z) · hit during market hours · 2 other RADX headline(s) in the window, move may be shared
day 0 close
+28.9%
day 1 · peak
+50.4%
day 3
+35.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics received IND approval from the US FDA.
  • The company is advancing its Phase 1/2a clinical study of BetaBart (RV-01).
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• January 10, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• November 29, 2022
• Updates
• June 28, 2024
• Announcements , Updates
• July 22, 2025
• Announcements
• November 21, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the IND approval?

The IND approval allows Radiopharm to initiate a Phase I therapeutic clinical study targeting B7H3 with BetaBart.

What clinical study has Radiopharm initiated?

Radiopharm has initiated a Phase 1/2a clinical study of BetaBart (RV-01).

What updates has Radiopharm provided?

Radiopharm has provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1 B7H3 IND approval
Last updated: Jan 10, 2025